1. Antibody

    Comments Leave a Comment

    1-15 of 134 1 2 3 4 5 6 7 8 9 »
    1. Mentioned In 134 Articles

    2. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      ...tion with granulocyte-macrophage colony-stimulating factor. The influence of body weight and human anti-human antibody (HAHA) on the pharmacokinetics (PK) of hu3F8, and the effect of de novo anti-GD2 response on patient ...
      Read Full Article
      Mentions: Antibody
    3. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      ...arol E, Loibner H, Ladenstein R, Lode HN Immunotherapy with short term infusion (STI) of monoclonal anti-GD2 antibody (mAb) ch14.18 (4 × 25mg/m2/d; 8-20h) in combination with cytokines and 13-cis retinoic acid (RA) prol...
      Read Full Article
    4. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      ...WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo A, Furman WL Anti-GD2 monoclonal antibodies (mAb), acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial inves...
      Read Full Article
    5. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers
      ... a weapon. They developed an antibody-drug conjugate (ADC) called D3-GPC2-PBD, which combined a very specific antibody that recognizes GPC2 with a potent chemotherapy drug that is internalized specifically by cancer cell...
      Read Full Article
    6. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

      ... been reported in clinical trials or in the published literature. Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric hi...
      Read Full Article
    7. Consolidation Therapy for Newly Diagnosed Pediatric High-Risk Neuroblastoma Patients Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplant, Anti-GD2 Antibody, GM-CSF, IL-2 and Haploidentical NK Cells.

      ...tic cell transplant (AHCT), and experimental immunotherapy with hu14.18K322A (a humanized anti-GD2 monoclonal antibody), GM-CSF, and IL-2, with or without the adoptive transfer of haploidentical natural killer cells (NKs...
      Read Full Article
      Mentions: Antibody NK Cells
    8. 1-15 of 134 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Antibody

    1. An anti-tumor antibody can improve adoptive T-cell therapy to a surprising extent.
      In Recruiting the Entire Immune System to Attack Cancer
    2. The antibody-driven innate response creates an environment such that when the T cells come in, they can kill the tumor. In its absence, the tumor cells establish an environment where the T cells don't work very well.
      In Recruiting the Entire Immune System to Attack Cancer
    3. One of the regulators we uncovered normally enhances effector T cell differentiation at the expense of generating memory T cells and T cells that orchestrate antibody production.
      In Important regulators of immune cell response identified